Eleven Therapeutics is pioneering the development of next-generation RNA therapeutics through its innovative xRNA platform, which integrates synthetic chemistry and artificial intelligence (AI) to enhance the efficacy and specificity of mRNA-based treatments. The company emphasizes the digital nature of RNA molecules, which allows for precise combinatorial searches and predictive modeling when combined with advanced DNA synthesis and sequencing technologies. By leveraging AI to navigate the vast chemical space of RNA, Eleven Therapeutics aims to optimize the safety, efficiency, and duration of therapeutic effects, thereby reimagining the potential of RNA as a therapeutic modality.

Central to Eleven Therapeutics' approach is the TERÅ beads platform, which utilizes a deep-learning framework to analyze the effects of various chemical modifications on oligonucleotide therapeutics. This end-to-end platform employs high-throughput combinatorial chemistry to create a diverse library of RNA molecules, each uniquely modified and tagged with DNA barcodes for easy identification. Through a systematic build-measure-learn process, the company incubates these modified RNA oligos with cells, measuring their effects and refining their structure-activity relationships (SAR) based on extensive data collection. This iterative process not only enhances the therapeutic potential of RNA molecules but also allows for in vivo validation, ensuring that only the most promising candidates advance to clinical testing.

United Kingdom

Eleven Therapeutics is a biotechnology company leading the AI revolution in nucleic acid therapeutics. They harness the power of combinatorial chemistry and AI to transform RNAi drug development into a programmable process.

Eleven Therapeutics

Company Details